August 15, 2012

NeoStem®

Fast Facts

Name:	NeoStem, Inc.	Stock Price:	$0.72	Average Volume (3 mos):	1.3 million
Industry:	Biotech / Cell Therapy	52 Week Range:	$0.30 – 0.96	Shares Outstanding:	150.2 million
Ticker (Exchange):	NBS (NYSE MKT)	Market Cap:	$108.1 million		

All figures as of 8/10/12



PCT CELL THERAPY SERVICES

Established Leader in Cell Therapy Services

- 150 years of combined management expertise in manufacturing, regulatory and commercialization for therapeutics development
- $8-10 million in annual historic revenues
- East Coast and West Coast cGMP manufacturing facilities

Outsourcers of Cell Therapy Services

- Baxter International Inc.
- ERYtech Pharma SA
- Hackensack University Medical Center
- ImmunoCellular Therapeutics, Ltd.
- IRX Therapeutics
- Islet Sciences, Inc.
- NC Medical Research
- Prima Biomed Ltd.
- RTI Biologics Inc.

AMORCYTE
A NeoStem Company

Emerging Leader in Cardiovascular Cell Therapy

- Lead product, AMR-001, an autologous adult stem cell therapy for the prevention of major adverse cardiac events following acute myocardial infarction (AMI)
- Launched Phase 2 clinical trial in 1Q-2012, data readouts expected 2H-2013
- Potential for multiple indications beyond STEMI (i.e., congestive heart failure, other related vascular insufficiencies)

PreSERVE AMI Trial Phase 2 Clinical Plan	
Indication	Post-AMI preservation of cardiac function
Number of Subjects, Sites	160 patients, 40+ sites
Primary Endpoint	Increased cardiac perfusion
Secondary Endpoints include	Left ventricular ejection fraction, clinical outcomes

Athelos

In Partnership with
Becton Dickinson (20% Owner)

Immunotherapy Platform

- Immune mediated diseases are a result of imbalance between T effector cells and T regulatory cells
- T-reg therapy represents a novel approach for restoring immune balance by enhancing T-reg cell number/function





Opportunities in Regenerative Medicine

- Very small embryonic-like stem cells, shown to have several characteristics generally found in embryonic stem cells
- Activities have received awards of > $2.5 million to support this work

VSEL Technology

Cellular Differentiation with an Eye Toward Macular Degeneration

Recent Business Highlights

- NBS stock increased > 50% since 6/18/12 announcement of Erye divestiture (expected to close 4Q2012)
- Company expects $12.3 million in cash and removal of $35 million in debt obligations through divestiture
    - 50% of cash already received or in escrow
- 3 month average daily trading volume 1.3 million shares
- Recently achieved the Golden Cross
- $17.6 million raised 2012 YTD through warrant exercises and equity sales
- Consolidated Boston, MA facility operations into PCT East and West Coast facilities to further cost savings
- Revenues grew 95% for continuing operations for six months ended 6/30/12 compared to prior year period
- Patient enrollment for PreSERVE Phase 2 clinical trial continues – data readout expected near end of 2013
- $3 million total active government grants awarded for VSEL Technology development
- Recent additions to management – Martin Schmieg, VP, Corporate Development and Jonathan Sackner-Bernstein, MD, FACC, VP, Clinical Development and Regulatory Affairs

NeoStem, Inc. (NYSE MKT: NBS)
420 Lexington Avenue, Suite 450
New York, NY 10170
212.584.4180
www.neostem.com

Dr. Robin L. Smith
Chairman and Chief Executive Officer
212.584.4174
rsmith@neostem.com